Ken Griffin Protagonist Therapeutics, Inc Transaction History

Citadel Advisors LLC

$483 Billion
Q2 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Protagonist Therapeutics, Inc stock. As of the latest transaction made, Citadel Advisors LLC holds 7,400 shares of PTGX stock, worth $339,216. This represents 0.0% of its overall portfolio holdings.

Number of Shares

7,400

Previous 10,900 32.11%

Holding current value

$339,216

Previous $315,000 18.73%

% of portfolio

0.0%

Previous 0.0%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$21.79 - $32.15 $48,983 - $72,273	-2,248 Reduced 4.7%	45,616 $1.32 Million
Q4 2023 Feb 14, 2024	SELL	$14.05 - $23.44 $41,194 - $68,726	-2,932 Reduced 5.77%	47,864 $1.1 Million
Q3 2023 Nov 14, 2023	SELL	$16.68 - $23.66 $8.31 Million - $11.8 Million	-498,198 Reduced 90.75%	50,796 $847,000
Q2 2023 Aug 14, 2023	SELL	$18.02 - $29.36 $11.1 Million - $18.1 Million	-615,686 Reduced 52.86%	548,994 $15.2 Million
Q1 2023 May 15, 2023	SELL	$10.78 - $25.38 $12.8 Million - $30.2 Million	-1,190,634 Reduced 50.55%	1,164,680 $26.8 Million
Q4 2022 Feb 14, 2023	BUY	$7.36 - $11.17 $11 Million - $16.6 Million	1,488,927 Added 171.85%	2,355,314 $25.7 Million
Q3 2022 Nov 14, 2022	BUY	$7.86 - $11.71 $6.23 Million - $9.28 Million	792,258 Added 1068.76%	866,387 $7.3 Million
Q2 2022 Aug 15, 2022	SELL	$7.06 - $25.52 $795,626 - $2.88 Million	-112,695 Reduced 60.32%	74,129 $586,000
Q1 2022 May 16, 2022	BUY	$23.34 - $36.08 $3.53 Million - $5.46 Million	151,276 Added 425.55%	186,824 $4.42 Million
Q4 2021 Feb 14, 2022	SELL	$17.63 - $37.1 $1.47 Million - $3.09 Million	-83,156 Reduced 70.05%	35,548 $1.22 Million
Q3 2021 Nov 15, 2021	SELL	$12.95 - $49.69 $3.68 Million - $14.1 Million	-284,504 Reduced 70.56%	118,704 $2.1 Million
Q2 2021 Aug 16, 2021	BUY	$25.57 - $44.88 $5.24 Million - $9.2 Million	204,990 Added 103.42%	403,208 $18.1 Million
Q1 2021 May 17, 2021	SELL	$19.02 - $31.15 $2.71 Million - $4.44 Million	-142,604 Reduced 41.84%	198,218 $5.13 Million
Q4 2020 Feb 16, 2021	BUY	$18.49 - $25.13 $6.3 Million - $8.56 Million	340,822 New	340,822 $6.87 Million
Q2 2020 Aug 14, 2020	SELL	$6.19 - $18.84 $2.9 Million - $8.84 Million	-469,212 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$5.4 - $9.22 $54,642 - $93,297	10,119 Added 2.2%	469,212 $3.31 Million
Q4 2019 Feb 14, 2020	BUY	$4.69 - $13.45 $200,910 - $576,171	42,838 Added 10.29%	459,093 $3.24 Million
Q3 2019 Nov 14, 2019	BUY	$9.41 - $16.56 $60,299 - $106,116	6,408 Added 1.56%	416,255 $5 Million
Q2 2019 Aug 14, 2019	BUY	$8.98 - $12.96 $414,157 - $597,715	46,120 Added 12.68%	409,847 $4.96 Million
Q1 2019 May 15, 2019	BUY	$6.5 - $13.77 $2.14 Million - $4.53 Million	328,965 Added 946.34%	363,727 $0
Q4 2018 Feb 14, 2019	SELL	$6.3 - $10.44 $6,268 - $10,387	-995 Reduced 2.78%	34,762 $233,000
Q3 2018 Nov 13, 2018	SELL	$6.82 - $11.26 $652,292 - $1.08 Million	-95,644 Reduced 72.79%	35,757 $0
Q2 2018 Aug 10, 2018	BUY	$5.99 - $9.1 $492,401 - $748,056	82,204 Added 167.09%	131,401 $0
Q1 2018 May 11, 2018	BUY	$8.46 - $23.08 $416,206 - $1.14 Million	49,197 New	49,197 $423,000

Others Institutions Holding PTGX

# of Institutions

212

Shares Held

59.1M

Call Options Held

19K

Put Options Held

107K

View Full List

About Protagonist Therapeutics, Inc

Ticker PTGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,084,100
Market Cap $2.25B
Description
Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...

More about PTGX

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account